Validation of a predictive model for platelet transfusion refractoriness in patients with hematological diseases
Journal Title: Chinese Journal of Blood Transfusion - Year 2025, Vol 38, Issue 4
Abstract
[Objective] To validate and optimize the platelet transfusion refractoriness (PTR) prediction model for patients with hematological disorders established by our center. [Methods] The data of patients with hematological diseases who received platelet transfusions from December 2021 to December 2022 were used as the training set, and data from January 2023 to December 2023 as the validation set. The validation set data was used to validate the predictive model constructed on the training set. Relevant risk factors for PTR were collected through literature review and preliminary studies。 The patients were divided into effective and ineffective groups according to the corrected count increment (CCI) of platelet counts. Predictive factors were screened using univariate and multivariate logistic regression. The calibration of the model were assessed via calibration curves, while discrimination, accuracy, sensitivity, and specificity were evaluated using receiver operating characteristic (ROC) curves Clinical utility was further analyzed with decision curve analysis (DCA). [Results] The Hosmer-Lemeshow (H-L) goodness-of-fit test for the validation set yielded S: P=0.000, indicating that the original model needs optimization. Baseline comparisons and logistic regression identified the number of red blood cell units (RBCU) and platelet units (PLT-U) transfused as key predictors for the optimized model. The H-L goodness-of-fit test S: P values for the training and validation sets were 0.930 and 0.056, respectively; the ROC areas were 0.793 5 and 0.809 4, specificities 90.95% and 84.21%, sensitivities 59.26% and 70.04%, and accuracies 78.14% and 74.10%, respectively. DCA demonstrated clinical net benefit within a prediction probability threshold range of 0.2-0.8. [Conclusion] Transfusion volumes of RBC-U and PLT-U were inversely associated with PTR in hematological patients. The resulting PTR prediction model exhibits moderate predictive efficacy and clinical benefit.
Authors and Affiliations
Xiulan HUANG, Shuhan YUE, Qun CAI, Liqi LU, Mengzhen HE, Qiao LEI, Caoyi LIU, Jingwei ZHANG
Keywords
Related Articles
- EP ID EP766600
- DOI 10.13303/j.cjbt.issn.1004-549x.2025.04.012
- Views 10
- Downloads 0
Platelet apheresis status of blood donors in an island city
Objective To study the characteristics of voluntary apheresis platelet donors in Zhoushan Islands and its influence on the collection and supply of apheresis platelets. Methods From January 1, 2017 to December 31, 2021,...
Clinical observations of the therapeutic effect of CLAG or FLAG bridging BuCy conditioning regimen in the treatment of childhood acute leukemia
Objective To determine the therapeutic efficacy of cladribine combined with BuCy conditioning regimen for childhood acute leukemia, and compare it with fludarabine. Methods The clinical data of 70 children with acute leu...
Establish deferral criterion for HIV serological testing in blood donors
Objective To establish deferral criterion of HIV ELISA (enzyme-linked immunosorbent assay) and electrochemiluminescence immunoassay(ECLIA) by using receiver operating characteristic curve(ROC) method to screen HIV reacti...
Research progress on hepatitis E virus and blood safety
Hepatitis E virus (HEV) is one of the main reasons of acute viral hepatitis. Although the majority of hepatitis E virus infection in humans is transmitted by fecal-oral route around the world, transfusion-transmitted HEV...
Application of Z-score in retrospective analysis of external quality assessment for nucleic acid testing
[Objective] To use the Z-scores as a means of evaluating the results of external quality assessment (EQA), so as to improve the quality control management in laboratories. [Methods] Z-scores control charts were plotted b...